Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Automating neoantigen selection for personalized cancer vaccine design.
Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026
Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation.
Journal: Clinical genitourinary cancer
Published: June 26, 2026
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Journal: Journal for immunotherapy of cancer
Published: April 07, 2026
Evaluating Interim Progression: First Posttherapy 177Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 22, 2026
Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.
Journal: International journal of molecular sciences
Published: March 17, 2026
AR and Beyond: ctDNA Maps Resistance Evolution in mCRPC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 27, 2026
Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate.
Journal: Cancer discovery
Published: January 11, 2026
IL-7: a potential next-generation adjuvant for immune cell therapies.
Journal: Frontiers in immunology
Published: October 31, 2025
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: October 26, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2025
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Journal: Nature communications
Published: July 25, 2025
Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic.
Journal: Molecular cancer
Published: June 17, 2025
Last Updated: 09/26/2026